(Press-News.org) Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy
Inhibiting the myeloid mimicry pathway along with immunotherapy improves antitumor outcomes in preclinical models
Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.
The study, published today in Nature Communications, was led by Pavlos Msaouel, M.D., Ph.D., Giannicola Genovese, M.D., Ph.D., both associate professors of Genitourinary Medical Oncology, and Jianjun Gao, M.D., Ph.D., professor of Genitourinary Medical Oncology, and Linghua Wang, M.D., Ph.D., associate professor of Genomic Medicine, associate member of the James P. Allison Institute™ and focus area co-lead for the Institute for Data Science in Oncology.
“We identified a myeloid mimicry pathway that can drive tumor hyper progression following immunotherapy in renal medullary carcinoma. Inhibiting this pathway may offer a promising strategy to advance into clinical studies,” Msaouel said.
What is renal medullary carcinoma (RMC) and why is it hard to treat?
RMC is a type of kidney cancer that usually affects young people with sickle cell trait. Previous studies showed that RMC is resistant to immunotherapy and can lead to a poor prognosis. Not only that, but a particular mechanism called myeloid mimicry – a cancer cell’s ability to imitate myeloid cells to hide from the immune system – is thought to contribute to immune resistance and disease progression.
To provide more insights into this mechanism, the researchers examined single-cell RNA sequencing data from patients with RMC who were treated with nivolumab and ipilimumab combination immunotherapy.
What doesthis study mean for patients with treatment-resistant cancers?
The researchers identified specific targets in the myeloid-related pathways of RMC tumor cells that led to immunotherapy resistance and, one in particular – p300 – that when activated, leads to disease hyper progression.
Interestingly, studies have shown that high expression of p300 is associated with a poor prognosis in other solid tumors. The researchers targeted this pathway in preclinical models of RMC using a p300 selective inhibitor developed by MD Anderson’s Therapeutics Discovery division. When combined with immunotherapy, this inhibitor prevented hyper progression and improved immune response.
These results suggest that inhibiting this myeloid mimicry mechanism by adding epigenetic modulators to immunotherapy could be an effective approach to improve outcomes for patients with treatment-resistant cancers.
***
This study was supported by the National Cancer Institute, MD Anderson, Bristol Myers Squibb, the U.S. Department of Defense, the Cancer Prevention and Research Institute of Texas, the Andrew Sabin Family Foundation Fellowship, Gateway for Cancer Research, the Kidney Cancer Association, the V Foundation, the Renal Medullary Carcinoma Research Foundation, the Chris “CJ” Johnson Foundation, and The Mark Foundation for Cancer Research. For a full list of collaborating authors, disclosures and funding sources, see the full paper in Nature Communications.
END
Study identifies target for disease hyper progression after immunotherapy in kidney cancer
2025-11-25
ELSE PRESS RELEASES FROM THIS DATE:
Concordia researchers identify key marker linking coronary artery disease to cognitive decline
2025-11-25
Individuals with coronary artery disease (CAD) — a constricting or blocking of blood vessels feeding the heart — face increased risks of strokes, cognitive impairment and dementia. However, the link between CAD and cognitive function is not fully understood.
A new study led by Concordia researchers looks at how the disease affects the brain’s white matter, the network of nerve fibers that connects different regions of the brains and is critical to transmitting information efficiently.
The study, published in the journal Journal ...
HER2-targeted therapy shows promising results in rare bile duct cancers
2025-11-25
HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the HERIZON-BTC-01 clinical trial, the largest study of a HER2-targeted drug in BTC, show zanidatamab has clinically meaningful responses
The targeted therapy demonstrated durable responses, longer survival and tumor shrinkage in some BTC patients
Zanidatamab was granted accelerated FDA approval for treating HER2-positive BTC in Nov. 2024, based on these trial results
Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive ...
Metabolic roots of memory loss
2025-11-25
For decades, scientists have known that what harms the body often harms the brain. Conditions such as obesity, high blood pressure and insulin resistance strain the body’s vascular and metabolic systems. Over time, that stress can speed up cognitive decline and increase the risk of Alzheimer’s disease.
Now, researchers at Arizona State University and their collaborators report that these effects may begin far earlier than expected. In young adults with obesity, the team identified biological markers of inflammation, liver stress ...
Clinical outcomes and in-hospital mortality rate following heart valve replacements at a tertiary-care hospital
2025-11-25
Background and objectives
Mechanical valve replacement is a primary treatment for rheumatic heart disease, yet prosthesis-related adverse outcomes remain underreported in India. This study aimed to examine the in-hospital mortality rate among patients who underwent prosthetic heart valve replacement surgeries in the past five years.
Methods
A retrospective analysis of 221 rheumatic heart disease patients (2019–2023) who underwent aortic valve replacement (AVR), mitral valve replacement (MVR), or double valve replacement (DVR) was conducted. Comorbidities (hypertension, type-2 diabetes mellitus) and valve origin (Indian ...
Too sick to socialize: How the brain and immune system promote staying in bed
2025-11-25
“I just can’t make it tonight. You have fun without me.” Across much of the animal kingdom, when infection strikes, social contact shuts down. A new study details how the immune and central nervous systems implement this sickness behavior.
It makes perfect sense that when we’re battling an infection, we lose our desire to be around others. That protects them from getting sick and lets us get much needed rest. What hasn’t been as clear is how this behavior change happens.
In the research published Nov. 25 in Cell, scientists at The Picower Institute for Learning and Memory of MIT and collaborators used multiple methods to demonstrate ...
Seal milk more refined than breast milk
2025-11-25
Researchers at the University of Gothenburg have discovered that milk from grey seals in the Atlantic Ocean may be more potent than breast milk. An analysis of seal milk found approximately 33 per cent more sugar molecules than in breast milk. Many of these sugars are unique and may pave the way for even better infant formula for babies.
During the 17 days that grey seal pups suckle, they need to get their digestive systems up and running and build up an immune system to protect them against diseases and other dangers they may encounter in the North Atlantic. It is reasonable to suspect that their mother's milk is extremely refined to accomplish this task. ...
Veterans with cardiometabolic conditions face significant risk of dying during extreme heat events
2025-11-25
Veterans living in California who have cardiometabolic conditions such as diabetes and high blood pressure experience significantly higher risk of dying during heat waves compared to cooler days, UCLA-led research finds.
The study, to be published in the peer-reviewed JAMA Network Open, demonstrates the danger that heat waves can pose for people with heart disease and risk factors for heart disease, whether or not they are veterans, said Dr. Evan Shannon, assistant professor-in-residence at the David Geffen School of Medicine at UCLA and the study’s lead author. Veterans are particularly vulnerable to these heat events because they tend to be older, ...
How plants search for nutrients
2025-11-25
What makes plants tolerant to nutrient fluctuations? An international research team led by the Technical University of Munich (TUM) and involving the Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) has investigated this question on the micronutrient boron. The researchers analyzed 185 gene data sets from the model plant Arabidopsis. Their goal is to then be able to transfer the findings to the important crop plant rapeseed.
Boron is one of the key micronutrients for the growth and fertility of many plants. However, extreme weather events reduce the availability of this nutrient: drought reduces boron uptake, ...
Prefrontal cortex reaches back into the brain to shape how other regions function
2025-11-25
Vision shapes behavior and, a new study by MIT neuroscientists finds, behavior and internal states shape vision. The research, published Nov. 25 in Neuron, finds in mice that via specific circuits, the brain’s executive control center, the prefrontal cortex, sends tailored messages to regions governing vision and motion to ensure that their work is shaped by contexts such as the mouse’s level of arousal and whether they are on the move.
“That’s the major conclusion of this paper: There are targeted projections for targeted ...
Much-needed new drug approved for deadliest blood cancer
2025-11-25
Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with the deadliest form of blood cancer.
The federal Food and Drug Administration has approved the drug ziftomenib for patients with recurring or treatment-resistant acute myeloid leukemia who have a mutation in the NPM1 gene. The new medication, taken by mouth once daily, offers a potential treatment for patients who otherwise have no good options.
The drug arose from many years of research by Jolanta Grembecka, PhD, and Tomasz Cierpicki, PhD, who began the ...